目前，临床上HCC诊断的金标准依旧是病理组织学和/或细胞学检查，但由于该方法为有创性检查，使 用受到诸多条件限制，因此一般不作为首选的初诊方式。目前主流的首选诊断方法主要是血清学肿瘤标 志物检测和常规的影像学检测，但是我国HCC患者大多伴随基础肝病，超过80%的HCC发生在肝硬化基 础上，不典型增生结节或肝硬化背景使肝脏占位鉴别诊断困难而"辨不准"，因此，HCC 的精准诊断仍 面临着较大的挑战。近年来，以核医学为代表的分子影像检测技术发展迅速，其应用放射性药物与疾病 发生发展过程中的生物标志物特异性结合或参与生物代谢，在分子水平实现无创可视和量化评价而用于 疾病诊断，最常用的是氟-18-氟代去氧葡萄糖(F-FDG)PET 显像，然而，F-FDG 并非肿瘤特异性显像 剂，且由于HCC细胞膜葡萄糖转运蛋白表达低，文献报告F-FDG PET显像对HCC诊断的灵敏度仅为 36%-70%，美国国立综合癌症网路(National Comprehensive Cancer Network，NCCN)发布的指南不推荐 F-FDG 用于HCC诊断和评估。因此，开发高靶向HCC特异性分子探针是HCC精准个体化诊疗的重要发 展趋势 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 董事會欣然公告，本集團與武漢睿迪輻生物科技有限公司、傑科（天津）生物醫藥有 限公司合作開發的用於診斷肝細胞癌（hepatocellular carcinoma，HCC）的全球創新 放射性核素偶聯藥物「( RDC」) GPN02006 在中國開展的研究者發起的臨床研究（IIT 臨床研究），近日取得了里程碑式突破，並於成都 2025 未來 XDC 新藥大會中公開 發表了臨床結果。該研究是一項前瞻性、單中心、診斷性的臨床研究，在超過 80 例 臨床懷疑或者確診的 HCC 患者中，使用 GPN02006 並進行正電子發射斷層成像/電 腦斷層掃描（PET/CT）或正電子發射斷層成像/磁共振成像（PET/MRI）顯像，以初 步評估該產品對 HCC 的診 ...

百诺医药在资本市场上有丰富的经历。 IPO日报注意到，百诺医药曾于2016年3月24日登陆新三板挂牌，证券简称为百诺医药，证券代码为 836534，挂牌6年半后，在 2022年12月16日摘牌。 星标 ★ IPO日报 精彩文章第一时间推送 4月17日晚间，证监会官网披露，中信建投对辅导山东百诺医药股份有限公司（下称"百诺医药"）挂牌新三板并在北交所上市进 行了备案登记。 两年多前曾从新三板摘牌，后又创业板IPO失败，如今想重回新三板并在北交所上市的百诺医药怎么样了？ IPO日报注意到，百诺医药的2021年-2023 年营业收入和净利润的年复合增长率分别为43.98％、123.61％，业绩极为亮眼，毛 利率也高达76%以上。 制图：佘诗婕 净利润年复合增长率123.61％ 据悉，百诺医药成立于2000年8月，是一家贯穿药物研发及生产全生命周期的创新型一站式药物研发成果转化运营商，主要业务 分为三大部分，分别为医药研发CRO业务、医药生产CMO业务和原料药生产及销售业务，其中CRO业务以研发成果转化模式为 主。 （ Contract Research Organization ，即合同研究组织，指对外提供专业化药 ...

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [1]. Core Insights - The commercialization of nuclear medicine is accelerating, with significant growth in diagnostic nuclear drugs and the potential for domestic nuclear drugs to reach a commercialization inflection point [3][17]. - The report highlights the successful commercialization of Pluvicto and Lutathera, which are expected to generate substantial revenues, with Pluvicto projected to exceed $5 billion in peak sales [3][12]. - The report emphasizes the similarities between Radioligand Therapy (RDC) and Antibody-Drug Conjugates (ADC), suggesting that RDC could replicate the success of ADC in the market [3][22]. Summary by Sections Part 1: Overseas Nuclear Drug Rapid Growth, Domestic Commercialization Period - Overseas nuclear drugs are experiencing rapid commercialization, with Pluvicto achieving $1.392 billion in revenue in 2024, a 42% increase, and Lutathera generating $724 million, a 20% increase [3][12]. - The combined revenue from these two drugs for Novartis reached $2.116 billion, indicating the ongoing value realization of nuclear drugs [3][12]. - The report notes that the domestic nuclear drug market is set to expand significantly, with five new nuclear drugs approved since 2020, including Yttrium-90 microspheres from Yuan Da Pharmaceutical, which is expected to generate nearly HKD 500 million in revenue in 2024, a growth rate exceeding 140% [3][20]. Part 2: RDC Expected to Replicate ADC Success Path - RDC shares structural and mechanistic similarities with ADC, consisting of a targeting ligand, a linker, and a radioactive nuclide [3][22]. - The report outlines that both RDC and ADC have followed similar validation timelines, with ADC gaining market traction after the success of Enhertu, while RDC is now gaining attention following the success of Pluvicto [3][22]. - The market for new nuclear drugs is projected to reach approximately $4-5 billion in 2024, comparable to the ADC market size around 2021 [3][22]. Part 3: Domestic Nuclear Drug Pipeline Overview - The report details the current pipeline of domestic nuclear drugs, with three products in the NDA stage, including Novartis's PSMA diagnostic and therapeutic drugs [3][49]. - The leading targets in domestic research remain PSMA, FAP, and SSTR, with companies like Yuan Da Pharmaceutical and Xiantong Pharmaceutical leading in clinical project numbers [3][53]. - The anticipated approval of Novartis's two PSMA-targeted products in Q2 2025 is expected to further stimulate the domestic nuclear medicine market [3][20].

Summary of Conference Call Notes Company and Industry Overview - The conference call involved **Yuan Da Pharmaceutical**, discussing its performance and strategies in the **pharmaceutical industry**, particularly focusing on **nuclear medicine** and **innovative drug development** [1][2][29]. Key Points and Arguments Financial Performance - **Total revenue** for the year reached **HKD 11.64 billion**, a **12.8%** increase year-over-year [2]. - The **Hoya segment** showed remarkable growth, achieving **HKD 590 million** in revenue, up **176.6%** year-over-year, indicating strong innovation and market demand [2]. - The company maintained a **dividend payout** of **HKD 910 million**, consistent with the previous year [2]. Product Development and Innovation - A total of **33 products** were launched last year, including **2 innovative products** and **21 major milestones** in clinical trials [3]. - The company has expanded its product lines in various segments, including cardiovascular devices and respiratory products, contributing to sustained revenue growth [3][4]. - The **nuclear medicine** sector is highlighted as a key growth area, with ongoing collaborations with international firms like **Telix** and **IPM** to enhance product offerings [6][38]. Market Strategy and Future Outlook - The company aims to launch **23 innovative products** by **2025**, focusing on high-demand areas such as interventional medicine and respiratory treatments [24][25]. - There is a strong emphasis on expanding the **nuclear medicine** market, with plans to enhance clinical trial submissions to the **FDA** and **CDE** [50][51]. - The company is positioning itself as a leader in the **nuclear medicine** field, with a focus on addressing unmet clinical needs and expanding its global footprint [41][42]. Challenges and Responses - The pharmaceutical industry is undergoing significant reforms, presenting both opportunities and challenges. The company is adapting by enhancing its product pipeline and focusing on innovative solutions [1][5]. - The management expressed confidence in navigating financial pressures and emphasized a proactive approach to product development and market expansion [30][32]. Additional Important Content - The company has established a **global supply network** for nuclear medicine, covering over **50 countries** and regions, which is crucial for its international growth strategy [9]. - There is a notable increase in the **academic promotion team**, with a **90%** growth in team members and an **80%** increase in trained surgeons, which is expected to drive product adoption [10]. - The company is committed to maintaining a strong pipeline of **generic drugs** while transitioning towards more innovative products, reflecting a strategic shift in its business model [29][32]. This summary encapsulates the key insights from the conference call, highlighting the company's financial performance, product innovation, market strategies, and future outlook within the pharmaceutical industry.

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Viewpoints - The ongoing US-China tariff policies are causing disruptions, suggesting a focus on non-US market expansion and import substitution opportunities in the biopharmaceutical sector [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, with companies primarily exporting to markets outside the US being less affected [4][9] - The report emphasizes the potential for domestic products to gain market share in the biopharmaceutical sector due to increased tariffs on US imports [9][10] Summary by Sections Tariff Policy Overview - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [4][5] Biopharmaceutical Sector Insights - The blood products sector is expected to stabilize prices and increase the market share of domestic products due to tariff impacts on imports, particularly for albumin [9] - The medical device sector is anticipated to accelerate domestic substitution due to reliance on North American production, with specific focus on electrophysiology and imaging products [10] - The report suggests monitoring companies such as Palin Bio, Tian Tan Bio, and Huashan Bio for potential growth opportunities in the blood products market [9][10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [12] - Specific companies highlighted for innovation include BeiGene, Dongcheng Pharmaceutical, and others with strong global competitiveness [12] - Companies like Mindray Medical and United Imaging are noted for their potential in overseas markets [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, showing a 49% year-on-year increase in sales [13] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - The report also highlights the potential of companies like East China Pharmaceutical and others in the nuclear medicine sector [17] Market Performance - The biopharmaceutical sector has seen a decline of 5.61% recently, with specific sub-sectors experiencing varying levels of impact [31][44]

Core Viewpoint - The percutaneous coronary intervention (PCI) market in China is experiencing significant growth due to increasing rates of cardiovascular diseases driven by aging population and rising obesity rates, with the number of PCI procedures expected to reach 3.6 million by 2030 from 1.9 million in 2024 [1][11]. Industry Overview - PCI is a minimally invasive procedure aimed at improving blood flow in narrowed or blocked coronary arteries, with various techniques including balloon angioplasty and stent implantation [1][5]. - The PCI industry is supported by a supply chain that includes raw materials like stainless steel and cobalt-chromium alloys, as well as advanced medical devices and technologies [5]. Industry Environment - China has approximately 330 million patients with cardiovascular diseases (CVD), with a significant portion being elderly, which correlates with a rising incidence of heart diseases [7]. - The aging population in China is projected to increase from 145 million in 2015 to 220 million by the end of 2024, leading to a higher prevalence of cardiovascular diseases [7]. Industry Status - The total number of registered PCI cases in China reached 1,636,055 in 2023, marking a year-on-year growth rate of 26.44%, the highest recorded [9]. - National policies are enhancing healthcare services and infrastructure, leading to increased accessibility and acceptance of PCI procedures among patients [11]. Development Trends - The PCI industry is witnessing rapid technological innovation and product upgrades, with advancements in drug-eluting stents and biodegradable stents improving treatment outcomes and reducing complications [20]. - Market demand for PCI is expected to continue growing due to rising cardiovascular disease rates and increased public awareness of health [21]. - The industry faces intensified international competition, necessitating domestic companies to enhance innovation and expand into global markets [22]. Competitive Landscape - The PCI market in China is characterized by a mix of international giants like Medtronic and Abbott, and domestic companies such as Lepu Medical and Sino Medical, with the latter gaining market share through competitive pricing and innovative products [15][16]. - Companies like Weimai Medical and Yiju Medical are focusing on comprehensive solutions in interventional devices, with a strong emphasis on research and development [16][18].

证券研究报告 | 2025年04月11日 远大医药（00512.HK） 优于大市 2024 年归母净利同比增长 31%，核药龙头杨帆启航 收入同比增长 10.6%，归母净利润同比增长 31.3%。2024 年公司实现收入 116.45 亿港币，同比增长 10.6%，扣除汇率变动影响同比增长约 12.8%；实 现归母溢利 24.68 亿港币，同比增长 31.3%；若扣除对 Telix 投资的公允价 值变动收益（7.08 亿港币），正常化归母溢利约 17.61 亿港币，同比增长约 2.5%，进一步扣除汇率变动的影响后同比增长约 4.6%，在较大的外部环境压 力下保持业绩的良好增长。 五官科和呼吸类产品表现亮眼，核药抗肿瘤板块持续高速放量。扣除汇率变 动影响，2024 年制药科技板块实现收入 73.18 亿港币，同比增长 9.6%，其 中呼吸及危重症业务收入 17.09 亿港币，同比增长约 26.9%，主要因为核心 产品切诺的临床需求持续增长以及新产品恩卓润、恩明润和布地奈德鼻喷雾 剂的快速放量；五官科业务收入 27.04 亿港币，同比增长 19.3%，主要是新 品销售带来增长；心脑血管急救业务收入 21.76 亿 ...